Ligand Pharmaceuticals | LGND - Ebitda


Ligand Pharmaceuticals reported $150.32M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 5.14B 775M Dec/2025
Anika Therapeutics USD -2.69M 4.73M Mar/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
Baxter International USD 426M 36M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Enviri Corporation USD 70.13M 4.29M Dec/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -314.19M 31.48M Dec/2025
Intrexon USD -24.7M 2.92M Jun/2024
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 150.32M 129.42M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Pacira USD 38.71M 10.65M Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Veracyte USD 42.31M 2.58M Dec/2025